All In Biotech

Drug Trial Radar · NCT07098988

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

107

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Mar 31, 2029

Study completion Mar 31, 2031

Sponsor

Lead sponsor
CatalYm GmbHIndustry
Sponsor type
Industry
First posted
Aug 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed, Carboplatin) in the first-line treatment of participants with newly diagnosed metastatic non-squamous NSCLC. The trial consists of 3 Parts, a non-randomized Safety-run-in part (Part A) and the subsequent randomized Ph2b trial with 2 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Conditions

  • Metastatic Non-Squamous Non-Small Cell Lung Cancer
  • Adult Solid Tumor

Interventions

  • VisugromabBiological

    Participants receive Visugromab (recommended dose) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.

  • Matching placebo for visugromabDrug

    Participants receive Matching Placebo intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.

  • Pembrolizumab 200 mg Q3WBiological

    Participants receive Pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion.

  • Pemetrexed 500 mg/m^2Drug

    Participants receive Pemetrexed 500 mg/m\^2 IV on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.

  • Carboplatin AUC 5Drug

    Participants receive Carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) on Day 1 of each 21-day cycle for four cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: up to 24 months

Locations

51 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Smilow Cancer Center, Derby

    Derby, Connecticut · Recruiting

  • Smilow Cancer Center, Guilford

    Guilford, Connecticut · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital - North Haven

    North Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital - Trumbull

    Trumbull, Connecticut · Recruiting

  • Smilow Cancer Hospital - Waterbury

    Waterbury, Connecticut · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • NYU Longone Health

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Thorax Clinic Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • University Hospital Würzburg

    Würzburg, Bavaria, Germany · Recruiting

  • Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift

    Bielefeld, North Rhine-Westphalia, Germany · Recruiting

  • Clinics Essen-Mitte

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • Foundation Bethanien Moers

    Moers, North Rhine-Westphalia, Germany · Recruiting

  • Großhansdorf Hospital - Clinical Center for Pulmonology and Thoracic Surgery, Department of Thoracic Oncology

    Großhansdorf, Schleswig-Holstein, Germany · Recruiting

  • Oncology Reference Center

    Aviano, Italy · Recruiting

  • Local Health Unit of Romagna - Santa Maria delle Croci Hospital of Ravenna, Onco-Hematology Department

    Ravenna, Italy · Recruiting

  • National Cancer Institute Regina Elena, IRCCS

    Rome, Italy · Recruiting

  • Institute of Cancer Research and Treatment of Candiolo

    Candiolo, Candiolo, Italy · Recruiting

  • Institute of Romagna for Cancer Research " Dino Amadori" - IRCCS IRST

    Meldola, Forli, Italy · Recruiting

  • National Cancer Institute, IRCCS

    Milan, Milan, Italy · Recruiting

  • MED-Polonia, Sp. z o.o. (LLC)

    Poznan, Poland · Recruiting

  • Specialist Hospital in Prabuty Sp. z o.o. (LLC), Department of Pulmonology

    Prabuty, Poland · Recruiting

  • University Teaching Hospital No. 4 in Lublin, Multi-Profile Non-Invasive Treatment Department

    Lublin, Lublin Voivodeship, Poland · Recruiting

  • Gral Medical S.R.L. - Oncofort Hospital

    Piteşti, Romania · Recruiting

  • Clinica Polisano S.R.L.

    Sibiu, Romania · Recruiting

  • SC Oncomed SRL, Department of Medical Oncology

    Timișoara, Romania · Recruiting

  • "Sf. Nectarie" Oncology Center, Department of Medical Oncology

    Craiova, Dolj, Romania · Recruiting

  • University Hospital Lucus Augusti (HULA)

    Lugo, Spain · Recruiting

  • MD Anderson International Cancer Center Spain

    Madrid, Spain · Recruiting

  • University Hospital of Jaen

    Jaén, Andalusia, Spain · Recruiting

  • Regional University Hospital of Malaga

    Málaga, Andalusia, Spain · Recruiting

  • University Hospital Virgen Macarena

    Seville, Andalusia, Spain · Recruiting

  • University Hospital Virgen del Rocio (HUVR)

    Seville, Andalusia, Spain · Recruiting

  • University Hospital Marques de Valdecilla (HUMV)

    Santander, Cantabria, Spain · Recruiting

  • Hospital del Mar

    Barcelona, Catalonia, Spain · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.